A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg
He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his thoughts on tolerability, compliance, the development of oral GLP’s, business development, and more.